STAT Summit

Hear industry analysis from the top executives, researchers, policymakers, and patient advocates who have spoken at past STAT Summits. See our list of stories from past summits below.

All Coverage

STAT Summit By Elizabeth Cooney

Bill Gates worries about a ‘dysfunctional’ approach to Covid-19 vaccine distribution

Health By Andrew Joseph

Fauci suggests he should have been ‘much more vocal’ about Covid-19 testing early in pandemic

STAT Summit By Helen Branswell

STAT Summit: A conversation with Anthony Fauci, America’s virologist

STAT Summit By Eric Boodman

Hopeful Covid-19 vaccine data won’t help hospitals that are overstretched now, experts say

STAT Summit By STAT staff

Watch: VCs have to predict the future. Here’s what three of them expect next in biotech

STAT Summit By STAT staff

A conversation with cancer researcher Charles Sawyers, winner of the first STAT Biomedical Innovation Award

STAT Summit By STAT staff

Watch: CEO Daniel O’Day says Gilead is in a ‘sweet spot.’ What’s next?

STAT Summit By STAT staff

Watch: Top Biogen scientist explains why he’s confident in company’s drug for Alzheimer’s

Biotech By Nicholas Florko

This invite-only club is grooming new biotech CEOs — and helping make them less lonely, too

Politics By Nicholas Florko

Our drug policy often prioritizes eliminating rare disease. One researcher asks: Is that the right goal?

The Readout LOUD By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Listen: Warren’s awkward home front, the ethics of treating dwarfism, and the sound of STAT Summit

STAT Summit By STAT staff

Watch: The state of biotech at time of innovation — and high prices

Politics By Nicholas Florko

As FDA toils over how to regulate CBD, frustration builds on all sides

Pharmalot By Ed Silverman

Having gobbled up Celgene, the Bristol-Myers CEO ducks questions about his key rival

STAT Summit By Casey Ross

A bold prediction: Machine learning will yield new drug candidates within three years

Biotech By Damian Garde

Most Read

Gene therapy pioneer says the field is behind — and that delivery technology is ‘embarrassing’

Biogen’s top scientist nearly dares FDA not to approve Alzheimer’s drug

‘The industry has earned it’: Three CEOs own up to biopharma’s bad reputation

Watch: Dr. James Wilson, a scientific pioneer, on the future of gene therapy

Longtime cancer researcher Charles Sawyers named first STAT Biomedical Innovation Award winner

STAT Summit: The hypebusters who spoke truth to power

Watch: What patients and their families learned from facing a deadly disease

Watch: Top FDA official talks bringing the agency into a new age

All Coverage

Bill Gates worries about a ‘dysfunctional’ approach to Covid-19 vaccine distribution

Fauci suggests he should have been ‘much more vocal’ about Covid-19 testing early in pandemic

STAT Summit: A conversation with Anthony Fauci, America’s virologist

Hopeful Covid-19 vaccine data won’t help hospitals that are overstretched now, experts say

Watch: VCs have to predict the future. Here’s what three of them expect next in biotech

A conversation with cancer researcher Charles Sawyers, winner of the first STAT Biomedical Innovation Award

Watch: CEO Daniel O’Day says Gilead is in a ‘sweet spot.’ What’s next?

Watch: Top Biogen scientist explains why he’s confident in company’s drug for Alzheimer’s

This invite-only club is grooming new biotech CEOs — and helping make them less lonely, too

Our drug policy often prioritizes eliminating rare disease. One researcher asks: Is that the right goal?

Listen: Warren’s awkward home front, the ethics of treating dwarfism, and the sound of STAT Summit

Watch: The state of biotech at time of innovation — and high prices

As FDA toils over how to regulate CBD, frustration builds on all sides

Having gobbled up Celgene, the Bristol-Myers CEO ducks questions about his key rival

A bold prediction: Machine learning will yield new drug candidates within three years

Gilead CEO Daniel O’Day says company is in an ‘acquisitive mode’